Kotoe Takayoshi1,2, Keita Uchino1, Masahiro Nakano3, Koji Ikejiri4, Eishi Baba2,5. 1. a Department of Medical Oncology , Clinical Research Institute, National Hospital Organization Kyushu Medical Center , Fukuoka , Japan. 2. b Department of Hematology and Oncology , Kyushu University Hospital , Fukuoka , Japan. 3. c Department of Nursing , Faculty of Health Sciences, Junshin Gakuen University , Fukuoka , Japan. 4. d Department of Clinical Cancer Care , Clinical Research Institute, National Hospital Organization Kyushu Medical Center , Fukuoka , Japan. 5. e Department of Comprehensive Clinical Oncology , Faculty of Medical Sciences, Kyushu University , Fukuoka , Japan.
Abstract
BACKGROUND: Patients with advanced gastric cancer (AGC) often suffer weight loss, which can be used to predict prognosis. Few reports have assessed the correlation between weight loss during chemotherapy and survival in patients with AGC. METHODS: Fifty-three patients with histologically proven AGC, who started systemic chemotherapy from September 2010 to March 2014, were retrospectively examined for body weight, inflammatory status, and survival. Correlation analyses were performed between weight change and survival. Correlations between weight loss and the patient characteristics were analyzed by stepwise multiple regression analyses. RESULTS: The mean age of the patients was 64.4 years; 64% of the patients were males. Initial chemotherapy included fluoropyrimidine plus cisplatin (62%), fluoropyrimidine alone (26%), and other medications (12%); 72% of the patients exhibited weight loss during the initial therapy. Poorer mean overall survival and mean progression-free survival were observed in patients with weight loss of higher-than-average values than in those with weight loss of lower-than-average values. Serum C-reactive protein levels were significantly correlated with weight loss. CONCLUSIONS: Weight loss during initial chemotherapy for AGC may predict survival. Systemic inflammation is suggested to be associated with weight loss.
BACKGROUND:Patients with advanced gastric cancer (AGC) often suffer weight loss, which can be used to predict prognosis. Few reports have assessed the correlation between weight loss during chemotherapy and survival in patients with AGC. METHODS: Fifty-three patients with histologically proven AGC, who started systemic chemotherapy from September 2010 to March 2014, were retrospectively examined for body weight, inflammatory status, and survival. Correlation analyses were performed between weight change and survival. Correlations between weight loss and the patient characteristics were analyzed by stepwise multiple regression analyses. RESULTS: The mean age of the patients was 64.4 years; 64% of the patients were males. Initial chemotherapy included fluoropyrimidine plus cisplatin (62%), fluoropyrimidine alone (26%), and other medications (12%); 72% of the patients exhibited weight loss during the initial therapy. Poorer mean overall survival and mean progression-free survival were observed in patients with weight loss of higher-than-average values than in those with weight loss of lower-than-average values. Serum C-reactive protein levels were significantly correlated with weight loss. CONCLUSIONS:Weight loss during initial chemotherapy for AGC may predict survival. Systemic inflammation is suggested to be associated with weight loss.
Authors: Fatouma Alimirah; Tanya Pulido; Alexis Valdovinos; Sena Alptekin; Emily Chang; Elijah Jones; Diego A Diaz; Jose Flores; Michael C Velarde; Marco Demaria; Albert R Davalos; Christopher D Wiley; Chandani Limbad; Pierre-Yves Desprez; Judith Campisi Journal: Cancer Res Date: 2020-07-08 Impact factor: 12.701
Authors: Elaine B Trujillo; Katrina Claghorn; Suzanne W Dixon; Emily B Hill; Ashlea Braun; Elizabeth Lipinski; Mary E Platek; Maxwell T Vergo; Colleen Spees Journal: J Oncol Date: 2019-11-22 Impact factor: 4.375